Thompson Cancer Survival Center – Clinical Trials
Clinical Trials
Clinical trials are research studies designed to discover new ways to treat different cancers and directly impact the number of new therapies and treatments available to fight cancer. Today’s trials are tomorrow’s standard of cancer care.
Thompson was the first to bring cancer clinical trials to East Tennessee over 25 years ago. Today, Thompson’s clinical trials department is under the leadership of David Chism, MD, and Kristi Simcox, BS, CCRP, System Director of Clinical Research. Our oncologists are certified to participate in clinical trials and work with multiple cancer research groups to bring innovative treatments to East Tennessee. In addition, we partner with pharmaceutical companies to give our patients access to new treatments not otherwise available. We offer clinical trials because they often lead to better ways to diagnose, treat, and prevent cancer, allowing people to live healthier and longer lives. Ask your doctor if a clinical trial might be right for you.
Thompson Cancer Survival Center offers clinical trials at the following Thompson Oncology Group locations:
- Blount
- Downtown Knoxville
- Lenoir City
- Oak Ridge
- West Knoxville
Our Team
Name | Title | Contact Info |
David Chism, MD | Medical Director of Clinical Research | [email protected] | 865-331-1812 |
Kristi Simcox, BS, CCRP | Systems Director of Clinical Research | [email protected] | 865-331-4985 |
Jessica Severt, RN, BSN | Study Coordinator | [email protected] | 865-331-4966 |
Ashley Lyons, RN | Study Coordinator | [email protected] | 865-331-2586 |
Sarah France, RN | Study Coordinator | [email protected] | 865-331-2587 |
Casey Mastio-Partridge | Study Coordinator | [email protected] | 865-331-1812 |
Christina Haller | Regulatory Specialist | [email protected] | 865-331-1902 |
Catherine Duke-Taylor | Regulatory Specialist | [email protected] | 865-331-1291 |
Active Clinical Trials
Breast
Protocol Number | NCT Number | Title | Principal Investgator |
WO42633 (Astefania) | NCT04873362 | A Phase III, Randomized, Double-Blind, Placebo-Controlled clinical trial to evaluate the efficacy and safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at high risk of recurrence following preoperative therapy | David Chism, MD |
D8534C00001 (Serena-6) | NCT04964934 | A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor | David Chism, MD |
ML43171 | NCT0536340 | A Phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of Giredestrant plus Everolimus compared with Exemestane plus Everolimus in patients with estrogen receptor-positive, her2- negative, locally advanced or metastatic breast cancer | David Chism, MD |
D9673R00025 (Destiny) DB-Respond | NCT05592483 | A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+ and HER2-low unresectable and/or metastatic breast cancer | David Chism, MD |
D926XC00001 (Tropion Breast-03) | NCT05629585 | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03) | David Chism, MD |
Esophageal
Protocol Number | NCT Number | Title | Principal Investigator |
MK3475-975 | NCT04210115 | A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) | David Chism, MD |
NRG-GI006 | NCT03801876 | Phase iii randomized trial of proton beam therapy (pbt) versus intensity modulated photon radiotherapy (imrt) for the treatment of esophageal cancer | David Chism, MD |
Gastrointestinal
Protocol Number | NCT Number | Title | Principal Investigator |
EA2176 | NCT04444921 | A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients | David Chism, MD |
Genitourinary
Protocol Number | NCT Number | Title | Principal Investigator |
H-300-001 | NCT05553639 | A Phase 1/2 Study of Replicating Arenavirus-based Vector(s) Encoding Prostate Cancer-Associated Antigens in Participants with Metastatic Castration-Resistant Prostate Cancer | David Chism, MD |
SGNDV-001 | NCT05911295 | An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater) | David Chism, MD |
D910PC00001 (VOLGA) | NCT04960709 | A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA) | David Chism, MD |
IMMU-132-06 | NCT03547973 | A Phase II Open-Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | David Chism, MD |
Kidney
Protocol Number | NCT Number | Title | Principal Investigator |
BO43936 (Triplet RCC) | NCT05805501 | A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations with Axitinib in patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | David Chism, MD |
XL092-304 (STELLAR) | NCT05678673 | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | David Chism, MD |
Leukemia/Lymphoma
Protocol Number | NCT Number | Title | Principal Investigator |
AZA-MDS-006 (CONNECT) | NCT01688011 | The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | David Chism, MD |
M22-132 | NCT05283720 | Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma | David Chism, MD |
C4971003 | NCT05626322 | A phase 1b/2 study of pf-07901801, a cd47 blocking agent, with Tafasitamab and Lenalidomide for participants with relapsed/refractory diffuse large b cell lymphoma not eligible for stem cell transplantation | David Chism, MD |
Melanoma
Protocol Number | NCT Number | Title | Principal Investigator |
EA6141 | NCT02339571 | Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | David Chism, MD |
Non-Small Cell Lung Cancer
Protocol Number | NCT Number | Title | Principal Investigator |
R3767-ONC-2235 | NCT05785767 | A randomized, double-blind phase 2/3 study of fianlimab (anti-lag-3 antibody) in combination with Cemiplimab (anti-pd-1 antibody) versus Cemiplimab monotherapy in first-line treatment of patients with advanced nonsmall cell lung cancer (nsclc) with tumors expressing pd-l1 ≥50% | David Chism, MD |
R3767-ONC-2236 | NCT05800015 | A randomized, double-blind phase 2/3 study of Fianlimab (anti-lag-3 antibody), Cemiplimab (anti-pd-1 antibody), and chemotherapy versus Cemiplimab and chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer (nsclc) irrespective of pd-l1 expression levels | David Chism, MD |
BX43361 | NCT05419375 | MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS | David Chism, MD |
BO42777 | NCT05170204 | A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER | David Chism, MD |
D926NC00001 (AVANZAR) | NCT05687266 | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | David Chism, MD |
Contact Us
Clinical Research Office
Thompson Cancer Survival Center
1915 White Avenue
Knoxville, TN 37916
Phone: (865) 331-1812
Monday – Friday, 8:00 am – 4:30 pm